Cipla announces Q4 FY1415 Audited Consolidated Financial Results

Cipla announces the next steps in its relationship with Serum Institute - an exclusive distribution agreement for flu vaccine ‘Nasovac-S’ for India

Cipla announces the launch of generic drug Sofosbuvir in India under the brand name ‘Hepcvir’

Stempeutics receives Advanced Therapy Medicinal Product (ATMP) classification from European Medicines Agency (EMA) for its novel stem cell drug “Stempeucel®”

Stempeutics receives US process patent for its novel stem cell drug “Stempeucel®”

Cipla wins USD 188.95 million of Global Fund ARV Tender

Cipla announces Q3 FY1415 Unaudited Consolidated Financial Results

Cipla’s U.K. subsidiary enters into a joint venture agreement with existing partners – Cooper Pharma and The Pharmaceutical Institute (PHI)

Medicines for Malaria Venture announces collaborations with Cipla and Strides

Cipla announces a distribution agreement with Serum Institute of India for affordable paediatric vaccines in Europe